In comparison, the combination of anti-PD-1 and B cell-specific loss of IL-35 resulted in an additional reduction in tumor growth in the KPC mouse model by augmenting the CD4+ effector T cell response, decreasing intratumoral Treg frequency, and increasing effector CD8+ T cell infiltration and IFN-γ expression (54). This evidence concerns the gene CD4 and neoplasm.